$MNKD

MANNKIND CORP (MNKD): Results of Operations and Financial Condition

MANNKIND CORP (MNKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update • Achieved three major catalysts to drive future growth: o Launched the pediatric indication of Afrezza ® following FDA approval o FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema

Original reporting
Published Aug 5, 2026, 8:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$MNKD
Bullish
high confidence
Mentioned
$MNKD
Relevance
8/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MNKDBullishMed
01

Why it matters

The filing combines (1) two FDA approvals that expand labeled use and delivery format, (2) positive MNKD-201 Phase 1b topline safety/tolerability in IPF, and (3) updated cash and financing details, which together can shift both commercial and clinical risk expectations.

02

Market read

Traders can reassess MNKD’s near-term growth trajectory based on FDA-driven label expansion and the timing of Furoscix ReadyFlow commercialization, alongside updated clinical development risk from MNKD-201.

03

What to watch

Furoscix ReadyFlow is expected to be commercially available in late August, so near-term revenue impact may lag the approval; INFLO-2 enrollment and future Phase 2 outcomes remain key uncertainties.

Relevance 8/10Novelty 8/10Timing: after-hours filing today, with conference call at 4:30 p.m. ET
alphai · Earnings readMNKD · second quarter of 2026 · ended June 30, 2026

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

Mixed quarter

Total revenues increased 43% to $109,374 (Dollars in thousands), supported by Furoscix, collaborations and services, and royalties, while Afrezza and V-Go revenue declined, gross margin percentage decreased, and research and development and selling, general and administrative expenses increased.

Revenue
$109,374
43% y/y
Afrezza
$17.0 million
(7 %) y/y

Key metrics

as reported
MetricValueq/qy/y
Total revenues, three months ended June 30, 2026GAAP$109,374 (Dollars in thousands)43%
Revenue from marketed products growth, Q2 2026 versus Q1 2026other27%27%
Cost of goods sold – commercial, excluding amortization of acquired intangible assets, three months ended June 30, 2026GAAP$14.4 million
Research and development expenses, three months ended June 30, 2026GAAP$18.0 million32%
Selling, general and administrative expenses, three months ended June 30, 2026GAAP$58.3 million84%
Total revenues, six months ended June 30, 2026GAAP$199,544 (Dollars in thousands)29%
Cost of goods sold – commercial, excluding amortization of acquired intangible assets, six months ended June 30, 2026GAAP$21.9 million
Research and development expenses, six months ended June 30, 2026GAAP$35.2 million43%
Selling, general and administrative expenses, six months ended June 30, 2026GAAP$112.4 million98%
Cash, cash equivalents and investments as of June 30, 2026GAAP$111 million
Private placement closed on July 24, 2026other$50 million
CVR payment triggered by FDA approval of Furoscix ReadyFlowother$45 million
Top 100 pediatric insulin writers that have prescribed Afrezzaother1 in 3
Integrated Delivery Networks doses purchased growth, Q2 2026 versus Q1 2026other36%36%
Nephrology units dispensed growth, Q2 2026 versus Q1 2026other67%67%

Segments

SegmentRevenueq/qy/y
AfrezzaReceived FDA approval on May 29, 2026 for use in children and adolescents ages 6 and older living with diabetes.$17.0 million(7 %)
FuroscixThe addition of Furoscix to the product portfolio followed the October 7, 2025 acquisition of scPharma.$22.2 millionN/A
V-GoNot provided.2,770 (Dollars in thousands)(33 %)
Collaborations and servicesThe increase was primarily attributable to increased product sold to UT and revenue earned related to the development of ralinepag DPI.35,022 (Dollars in thousands)53 %
RoyaltiesThe increase in royalties was due to UT’s increase in net revenue from sales of Tyvaso DPI.32,370 (Dollars in thousands)4 %

Forward-looking milestones outlook

  • NoteFuroscix ReadyFlow is expected to be commercially available in late August.
  • NoteRalinepag DPI is on track for IND filing by year end.

What drove it

  • Furoscix generated $22.2 million in net sales for Q2 2026 following its addition through the October 7, 2025 acquisition of scPharma.
  • Collaborations and services revenue increased primarily from increased product sold to UT and revenue earned related to ralinepag DPI development.
  • Royalties increased because UT increased net revenue from sales of Tyvaso DPI.
  • Afrezza received FDA approval on May 29, 2026 for children and adolescents ages 6 and older living with diabetes.
  • Furoscix ReadyFlow received FDA approval on July 23, 2026 for treatment of edema in adults with heart failure or chronic kidney disease.
  • Topline U.S. Phase 1b INFLO-1 data demonstrated safety and tolerability of nintedanib DPI in IPF patients.

Concerns

  • Afrezza revenue was 17,021 (Dollars in thousands), down (7 %) from 18,329 (Dollars in thousands).
  • V-Go revenue was 2,770 (Dollars in thousands), down (33 %) from 4,125 (Dollars in thousands).
  • Gross margin percentage decreased due to the inclusion of Furoscix, which has a lower gross margin percentage than Afrezza.
  • Research and development expenses increased 32% to $18.0 million and selling, general and administrative expenses increased 84% to $58.3 million.
  • The filing states that the $50 million private-placement proceeds will fund the $45 million CVR payment triggered by FDA approval of Furoscix ReadyFlow.

What to watch

  • Commercial availability of Furoscix ReadyFlow in late August.
  • Early adoption of pediatric Afrezza, for which 1 in 3 of the top 100 pediatric insulin writers have prescribed.
  • Furoscix adoption in Integrated Delivery Networks and nephrology, where doses purchased increased by 36% and nephrology units dispensed increased by 67% over Q1 2026.
  • Site activation and enrollment in the global Phase 2 INFLO-2 study of MNKD-201.
  • The planned ralinepag DPI IND filing by year end.

Balance sheet and cash flow

  • Cash, cash equivalents and investments as of June 30, 2026, totaled $111 million.
  • Closed $50 million private placement on July 24, 2026; proceeds will fund the $45 million CVR payment triggered by the FDA approval of Furoscix ReadyFlow.

Analysis

MannKind reported Q2 2026 total revenues of $109,374 (Dollars in thousands), an increase of 43% from $76,527 (Dollars in thousands). The increase reflected Furoscix entering the portfolio through the October 7, 2025 acquisition of scPharma, as well as higher collaborations and services revenue and royalties. Revenue from marketed products grew 27% from Q1 2026 to Q2 2026.

Furoscix contributed $22.2 million in Q2 2026 net sales, while Afrezza generated $17.0 million and V-Go generated 2,770 (Dollars in thousands). Afrezza declined (7 %) from 18,329 (Dollars in thousands), and V-Go declined (33 %) from 4,125 (Dollars in thousands). Furoscix operating indicators were positive, with Integrated Delivery Networks doses purchased increasing 36% over Q1 2026 and a record number of nephrology units dispensed, increasing by 67% over Q1 2026. The pediatric Afrezza launch also showed early adoption, with 1 in 3 of the top 100 pediatric insulin writers having prescribed.

The revenue mix added cost and spending pressure. Cost of goods sold – commercial, excluding amortization of acquired intangible assets, was $14.4 million versus $4.6 million, and the company said gross margin percentage decreased because Furoscix has a lower gross margin percentage than Afrezza. Research and development expenses increased 32% to $18.0 million, reflecting Furoscix ReadyFlow formulation development, higher personnel costs following the scPharma acquisition, and MNKD-201 development. Selling, general and administrative expenses rose 84% to $58.3 million as MannKind promoted and supported Furoscix and expanded field-based teams for the pediatric Afrezza and Furoscix ReadyFlow launches.

The quarter included three development and regulatory milestones: pediatric Afrezza approval on May 29, 2026, Furoscix ReadyFlow approval on July 23, 2026, and positive Phase 1b INFLO-1 data for MNKD-201 in IPF patients. Management expects Furoscix ReadyFlow to be commercially available in late August, has global Phase 2 INFLO-2 site activation and enrollment underway, and is on track for a ralinepag DPI IND filing by year end. Cash, cash equivalents and investments totaled $111 million as of June 30, 2026, and the company closed a $50 million private placement on July 24, 2026 to fund the $45 million CVR payment triggered by the Furoscix ReadyFlow approval.

Management, verbatim

This was a transformative period for MannKind, during which we delivered all three major catalysts we set out to achieve in 2026.

Michael Castagna, Chief Executive Officer of MannKind

Not in the filing

stated, not guessed
  • GAAP gross margin percentage and prior-year gross margin percentage.
  • GAAP operating income or loss.
  • GAAP net income or loss.
  • GAAP diluted earnings or loss per share.
  • Non-GAAP operating income or loss, net income or loss, and earnings per share.
  • Operating cash flow.
  • Free cash flow.
  • Debt balance.
  • Share repurchases and dividends.
  • Weighted-average shares outstanding.
  • Individual Q1 2026 revenue figures for Afrezza, Furoscix, V-Go, collaborations and services, royalties, and total revenues.
  • Formal quantitative revenue, gross-margin, operating-expense, or tax-rate guidance.
  • Prior outlook or prior guidance for comparison.
  • Full consolidated statements of operations, which were truncated in the provided filing text.

AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

This is an SEC 8-K (Item 2.02) with an attached earnings/business update covering Q2 2026 financials and several 2026 catalysts.

Company-level read

Ticker impact

$MNKDBullishHigh confidence
Context

MannKind reported Q2 2026 results and disclosed FDA approvals for Afrezza pediatric use and Furoscix ReadyFlow, plus Phase 1b IPF data.

Expected impact

Likely positive bias for MNKD on continued uptake of pediatric Afrezza and Furoscix ReadyFlow commercialization, with additional upside tied to INFLO-2 Phase 2 progress.

Evidence & confidence

The filing is a primary disclosure (8-K with EX-99.1) containing multiple discrete catalysts: two FDA approvals, a topline Phase 1b readout, and updated cash/financing details.

Market effects

Reinforces momentum in inhaled insulin and IV-equivalent diuretic delivery devices, potentially improving sentiment toward small-cap biopharma with near-term regulatory catalysts.

Primarily US-focused regulatory and commercialization news (FDA approvals) with limited direct regional spillover.

INFLO-2 is global and could broaden investor attention to international IPF trial execution and timelines.

Counterpoint

Despite multiple catalysts, the company’s R&D and SG&A expenses rose sharply, and Afrezza revenue declined year over year, which could temper near-term earnings power.

Key entities

  • MannKind Corporation

    Nasdaq-listed biopharmaceutical company reporting Q2 2026 results and multiple regulatory and clinical milestones.

  • Afrezza

    Inhaled insulin; FDA approval for pediatric use ages 6 and older reported, plus pediatric launch momentum.

  • Furoscix ReadyFlow

    Autoinjector for IV-equivalent diuretic therapy; FDA approval for edema in adults with HF or CKD reported.

  • MNKD-201 (nintedanib DPI)

    IPF program; positive Phase 1b INFLO-1 topline safety/tolerability data reported.

  • United Therapeutics (UT)

    Received $5 million payment disclosed as support for ralinepag DPI advancement.

Every MNKD earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$UTHRMedAI 9/10

FDA accepts United Therapeutics' ralinepag NDA for PAH

The FDA accepted United Therapeutics' NDA for ralinepag, a PAH treatment, with a PDUFA target date of June 24, 2027. The application is based on Phase III trial results showing a 55% reduction in clinical worsening events. If approved, ralinepag would be the first once-daily oral prostacyclin IP receptor agonist for PAH. The company also plans to develop a dry powder inhalation formulation with MannKind.

$MNKDMed

CT companies take different paths to finance growth

Three Connecticut firms outlined different financing paths. New Silver said it acquired Mayflower Venture Partners to expand lending in New England, with deal terms undisclosed. American Battery Materials filed to raise about $16.3M for Utah lithium and magnesium exploration, targeting production in 2029. MannKind raised $50M after FDA approval of Furoscix ReadyFlow, funding a $45M milestone payment and aiming for U.S. sales by end-August.

$MNKDMed

MannKind's Nintedanib DPI Shows Favorable Safety In IPF Patients

MannKind (MNKD) reported positive topline Phase 1b INFLO-1 results for nintedanib dry powder inhalation in idiopathic pulmonary fibrosis. In a randomized, double-blind, placebo-controlled trial of 27 patients, it met the primary objective of safety and tolerability, with no serious adverse events, GI effects, bronchospasm, or discontinuations. MannKind is enrolling Phase 2 INFLO-2.

$MNKDMedAI 8/10

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

MannKind (Nasdaq: MNKD) reported positive topline Phase 1b INFLO-1 results for nintedanib dry powder inhalation (DPI) in idiopathic pulmonary fibrosis. In 27 patients, it met safety and tolerability goals with no serious adverse events, no bronchospasm or diarrhea, and no discontinuations. Phase 2 INFLO-2 is enrolling about 210 patients.